000			01405 a2200409 4500
005			20250512132628.0
264		0	_c19690830
008			196908s 0 0 eng d
022			_a0009-9236
024	7		_a10.1002/cpt1969104449 _2doi
040			_aNLM _beng _cNLM
100	1		_aPerlroth, M G
245	0	0	_aCardiogenic shock: a review. _h[electronic resource]
260			_bClinical pharmacology and therapeutics _c
300			_a449-67 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aBlood Pressure
650	0	4	_aCardiac Output
650	0	4	_aDigitalis Glycosides _xtherapeutic use
650	0	4	_aDopamine _xtherapeutic use
650	0	4	_aGlucagon _xtherapeutic use
650	0	4	_aHeart Diseases _xetiology
650	0	4	_aHemodynamics
650	0	4	_aHumans
650	0	4	_aHydrocortisone _xtherapeutic use
650	0	4	_aIsoproterenol _xtherapeutic use
650	0	4	_aMetaraminol _xtherapeutic use
650	0	4	_aNorepinephrine _xtherapeutic use
650	0	4	_aPhenoxybenzamine _xtherapeutic use
650	0	4	_aPhentolamine _xtherapeutic use
650	0	4	_aPropranolol _xtherapeutic use
650	0	4	_aShock _xetiology
650	0	4	_aVascular Resistance
700	1		_aHarrison, D C
773	0		_tClinical pharmacology and therapeutics _gvol. 10 _gno. 4 _gp. 449-67
856	4	0	_uhttps://doi.org/10.1002/cpt1969104449 _zAvailable from publisher's website
999			_c4896532 _d4896532